newsfilter
← Latest News
Business Wire·

Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers

Additional capital brings total raised to $150 million in a Series C financing Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or